No Disease Activity Changes After Children With IBD Switched to Infliximab Biosimilar
A real world study in an adolescent and young adult inflammatory bowel disease (IBD) population found no significant differences in key laboratory markers or disease activity in patients who remained on the originator (Remicade) compared with those who switched to the biosimilar CT-P13 (Inflectra; infliximab-dyyb). Dosing regimens and the development of antidrug antibodies were also … Read more